Johnson & Johnson (JNJ) AGM 2026 summary

Opening remarks and agenda

• Meeting opened by the Corporate Secretary, outlining the agenda, business updates, and Q&A session.

• Executive committee, board of directors, and independent auditors present.

Financial performance review

• Operational sales grew 5.3%, and excluding Stelara, growth was 11.5%.

• Adjusted net earnings reached $26.2 billion; adjusted EPS was $10.79.

• Free cash flow was nearly $20 billion; share price rose 43%, total shareholder return 47.5%.

• Over $32 billion invested in R&D and acquisitions; pharmaceutical sales exceeded $60 billion.

Board and executive committee updates

• Two new board members welcomed: John Morikis and Daniel Pinto.

• Board composition and director selection focus on complementary skills and ethical standards.

• Five new directors added in the past five years; limits on outside board service enforced.